Advertisement
Australia markets closed
  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     
  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     
  • AUD/USD

    0.6604
    -0.0017 (-0.26%)
     
  • OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD

    2,366.90
    +26.60 (+1.14%)
     
  • Bitcoin AUD

    92,114.11
    -3,119.27 (-3.28%)
     
  • CMC Crypto 200

    1,260.37
    -97.64 (-7.19%)
     
  • AUD/EUR

    0.6128
    -0.0010 (-0.16%)
     
  • AUD/NZD

    1.0963
    -0.0006 (-0.05%)
     
  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     
  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     
  • FTSE

    8,433.76
    +52.41 (+0.63%)
     
  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

3 Reasons to Buy AbbVie and 2 Reasons Not to Buy

2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie's monoclonal antibody blockbuster therapy, Humira, which is on track to generate a second consecutive year of $20 billion-plus in revenue in 2022.